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 Abstract  
 Despite recent breakthroughs in identifying MAIT cell antigens, the precise requirements for in 
vivo MAIT cell responses to infection remain unclear. Using MR1 tetramers, the MAIT cell response 
was investigated in a model of bacterial lung infection employing riboflavin gene-competent and 
deficient bacteria. MAIT cells were rapidly enriched in the lungs of C57BL/6 mice infected with 
Salmonella Typhimurium, comprising up to 50% of T cells after one week. MAIT cell 
accumulation was MR1-dependent, required antigen derived from the microbial riboflavin synthesis 
pathway and did not occur in response to synthetic antigen, unless accompanied by a TLR agonist or 
by co-infection with riboflavin pathway-deficient S. Typhimurium. MAIT cell accumulation involved 
proliferation in the lungs and regional LN, and was associated with their long-term retention in the 
lungs. Lung MAIT cells from infected mice were mainly CD4-CD8- double negative or CD8+, 
displayed an activated/memory phenotype, and most expressed the transcription factor RORt. T-bet 
expression increased following infection. The majority produced IL-17 while smaller subsets 
produced IFN or TNF, detected directly ex vivo. Thus, the activation and expansion of MAIT cells 
coupled with their pro-inflammatory cytokine production, occurred in response to antigens derived 
from microbial riboflavin synthesis and was augmented by co-stimulatory signals. 
  
INTRODUCTION  
Mucosal-Associated Invariant T (MAIT) cells are emerging as an important class of T cell with 
features of both innate and adaptive immunity. The function of MAIT cells is still being elucidated, 
but a key role is suggested by their conservation across many mammalian species and their high 
abundance in human blood and mucosal tissues. MAIT cells recognize conserved microbial 
metabolites generated during riboflavin synthesis, captured by the monomorphic MHC related 
protein 1 (MR1)1-6. MAIT cells express a conserved  T cell antigen receptor (TCR), consisting of a 
near-invariant TCR-chain coupled with a restricted set of -chains that are relatively conserved in 
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humans and mice1-6. In mice, MAIT TCRs use TRAV1-TRAJ33 (V19-Jα33) generally assembled 
with TRBV19 (V6) or TRBV13 (V8)7-9. In humans most MAIT cells express TRAV1-2-TRAJ33 
(V7.2-J33), but TRAV1-2-TRAJ12 or TRAV1-2-TRAJ20 are also used8. These TCR-chains 
predominantly form receptors with TRBV20 (V2) or TRBV6 (V13) -chains9, although many 
other TRBV genes are also used at lower frequency8. 
 
To date, characterisation of MAIT cells in models of infectious diseases has largely depended on 
analysis of the DN T cell population and PCR detection of the V19J33 invariant TCR- chain as 
there is no V19-specific mAb, or the use of V19J33 TCR transgenic.C-/- mice5,10-13. While 
V19 is characteristic of MAIT cells, it is also expressed by non-MAIT T cells. In addition, most 
conventionally-housed inbred mice, with the exception of the wild-derived inbred CAST/EiJ strain 17,  
have very low numbers of blood and lymphoid MAIT cells compared with humans9, and while TCR 
transgenic models have been used to help circumvent this problem18,19, the relationship between 
MAIT cells generated in TCR transgenic versus wild-type mice is unclear. 
 
We recently identified by-products of microbial riboflavin synthesis as a major natural source of 
antigen (Ag) driving MAIT cell activation in vitro2,4,20. It is unclear whether this pathway is the 
exclusive source of antigen in vivo, as V chain and complementarity determining region (CDR)3 
diversity in MAIT TCRs and differential responses to diverse pathogens might reflect diversity in 
MAIT antigens21-23. Indeed, a number of MAIT cell antigens were identified, including 5-(2-
oxoepropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), 5-(2-oxoethylideneamino)-6-D-
ribitylaminouracil (5-OE-RU), 6,7-dimethyl-8-D-ribityllumazine (RL-6,7-diMe) and 7-hydroxy-6-
methyl-8-D-ribityllumazine (RL-6-Me-7-OH), which vary considerably in potency, as well as non-
stimulatory MR1 ligands including 6-formyl-pterin (6-FP), a natural breakdown product of folic acid 
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2,4
. 5-OP-RU and 5-OE-RU, the most potent MAIT cell antigens, are created from the riboflavin 
precursor 5-amino-6-D-ribitylaminouracil (5-A-RU) by non-enzymatic condensation with small 
ubiquitous metabolites methylglyoxal and glyoxal, respectively2. This finding has enabled the 
production of highly specific MR1-Ag-tetramers that stain all MAIT cells in mice and humans2. Here 
we have examined the behaviour, functionality and phenotype of mouse MAIT cells, detected using 
MR1-5-OP-RU tetramers, in a bacterial lung infection model in C57BL/6 mice. Our data reveal that 
MAIT cell activation and accumulation in vivo was dependent on the presence of a functional 
riboflavin synthesis pathway in the microbial pathogen and expression of MR1 in the host mice. The 
cell-surface phenotype and functional properties of MAIT cells indicate a responsiveness of MAIT 
cells to infection. These studies have substantially advanced our understanding of the functional 
capacity of MAIT cells in vivo. 
 
RESULTS 
MAIT cells accumulate in the lungs of mice following infection with Salmonella Typhimurium 
Using Salmonella enterica serovar Typhimurium (S. Typhimurium), we previously showed that the 
ability to stimulate MAIT cells in vitro depends on the presence of an intact microbial riboflavin 
pathway, specifically involving genes necessary for the production of riboflavin precursor 
compounds4 including 5-A-RU2. We showed how 5-A-RU recombines with small metabolites to 
form MAIT-activating ligands, including the most potent identified to date, 5-OP-RU2. Tetramers of 
human or mouse MR1 loaded with 5-OP-RU specifically detect MAIT cells in the respective 
species2,8,24,25. Mouse MR1-5-OP-RU tetramers were used here to identify MAIT cells (defined as 
TCR+MR1-5-OP-RU tetramer+ cells) in single cell suspensions derived from the lungs, reproductive 
tract, liver, spleen, thymus, blood and mesenteric lymph nodes of uninfected C57BL/6 mice. MAIT 
cells represented ~2% of -T cells in the reproductive tract, and about 0.5-2% of -T cells in lung, 
with lower proportions in blood and other organs (Fig. 1a), consistent with recent findings24. In 
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contrast, we could not detect MAIT cells from C57BL/6.MR1-/- mice (Fig. 1a), confirming earlier 
findings that MR1 is vital for MAIT cell development6,19. 
 
We next examined the impact of lung infection on MAIT cells in a model involving inoculation of 
mice with live-attenuated vaccine strain S. Typhimurium BRD50926,27. While S. Typhimurium is not 
a natural pathogen in the lung, it is known to activate MAIT cells in vitro and genetic manipulation of 
this bacterium now allows us to probe the Ag requirements for MAIT cell activation in vivo. 
Following intranasal infection with S. Typhimurium BRD509, there was a substantial enrichment of 
MAIT cells in the lungs of C57BL/6 mice such that they comprised 25-50% of all infiltrating lung 
-T cells after one week (Fig. 1b,c, Supplementary Fig. 1). MAIT cell enrichment was absent in 
C57BL/6.MR1-/- mice (Fig. 1b,c) and was blocked by treatment with MR1-specific mAbs, 26.5 or 
8F2.F928,29 (Fig. 1c, Supplementary Fig. 1). Thus the MAIT cell accumulation and enrichment in 
this model was MR1-dependent. The accumulation of lung MAIT cells was also dependent on the 
size of the bacterial inoculum (Fig. 1d) and peaked at day 7 post infection (d7 p.i.) (Fig. 1e).  
 
In vivo enrichment of MAIT cells post-infection requires antigen derived from a bacterial 
riboflavin pathway 
To confirm the requirement for microbial riboflavin metabolites in driving the in vivo MAIT cell 
response, we constructed a mutant strain of BRD509 in which ribD and ribH genes, which are co-
located in the Salmonella genome, were deleted; BRD509ribDH. While deficiency of the ribH gene 
does not impact on bacterial activation of MAIT cells2 the ribD gene is essential for production of the 
5-A-RU precursor to MAIT cell antigens 5-OP-RU and 5-OE-RU2. The mutant BRD509ribDH 
bacteria were first tested in vitro and bacterial supernatants were found to be deficient in their ability 
to stimulate reporter cells expressing a MAIT TCR (Jurkat.MAIT)4 in an MR1-dependent activation 
assay (Fig. 2a). By comparison, BRD509 supernatant (wt) caused up-regulation of CD69 on 
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Jurkat.MAIT reporter cells (Fig. 2a). Supernatant from the BRD509ribDH bacteria reconstituted 
with ribD and ribH genes (BRD509ribDH+ribDH) activated Jurkat.MAIT cells to wild-type levels 
(Fig. 2a), confirming previous in vitro results obtained with mutants of another Salmonella strain2. 
 
In contrast to S. Typhimurium BRD509, infection with BRD509ribDH bacteria did not evoke 
MAIT cell accumulation beyond the resident MAIT cell numbers in uninfected lungs (Fig. 2b,c). 
This lack of MAIT cell accumulation was unlikely the result of the reduced growth rate of 
BRD509ribDH since a 10-fold higher dose of BRD509ribDH bacteria was used, resulting in 
equivalent bacterial counts at day 7 (Supplementary Fig. 2), and non-MAIT -T cells still 
accumulated (Fig. 2b). Moreover, the non-responsiveness of MAIT cells to infection with 
BRD509ribDH Salmonella could be rescued if the bacteria were co-administered intranasally with 
synthetic MAIT cell antigen 5-OP-RU delivered i.n. (Fig. 2b,c) or i.v. (Supplementary Fig. 3). In 
contrast, co-administration of the BRD509 strain and the MR1-ligand 6-FP4, which does not activate 
MAIT cells, did not cause MAIT cell accumulation in the lungs (Fig. 2c, Supplementary Fig. 3), 
confirming the specificity of the response. Of note, 5-OP-RU alone caused no MAIT cell 
accumulation at any dose or time point tested, when delivered either intranasally or intravenously, 
suggesting that synthetic Ag alone is insufficient to induce the MAIT cell accumulation (Fig. 2f, 
Supplementary Fig. 3). This could reflect a requirement for co-stimulation provided by the 
BRD509ribDH bacteria or the unstable nature of free 5-OP-RU failing to produce sustained MAIT 
cell stimulation. To examine whether a co-stimulus could be furnished through TLRs, we inoculated 
mice with 5-OP-RU and TLR agonists S-[2,3-bis(palmitoyloxy)propyl] cysteine (Pam2Cys), CpG 
oligonucleotides or polyinosinic:polycytidylic acid (poly I:C). Pam2Cys is a synthetic mimic of the 
lipid component of TLR2 and TLR6 ligand macrophage activating lipopeptide-2 (MALP-2) and has 
been shown to be an agonist for TLR230,31. Poly I:C is a TLR3 agonist similar to double stranded 
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RNA32. CpG oligonucleotides stimulate through TLR933. Challenge with each TLR agonist by itself, 
or with the non-activating MR1 ligand 6-FP, led to a lesser (2-3-fold) enrichment for MAIT cells in 
the lungs suggesting co-stimuli alone can exert some influence on MAIT cells (Fig. 2d). In addition, 
although intranasal challenge with antigen alone did not induce accumulation of lung MAIT cells, it 
did induce rapid up-regulation of CD69 on MAIT cells in vivo as early as 2h following inoculation 
(Fig. 2e). However, the intranasal co-administration of synthetic antigen 5-OP-RU and Pam2Cys, 
poly I:C or CpG led to a 15-25 fold enrichment of MAIT cells in the lung in the absence of any 
bacterial challenge (Fig. 2d,f). At least for Pam2Cys plus 5-OP-RU, this response was sustained over 
time (not shown) and was largely blocked by administration of anti-MR1 mAb (Supplementary Fig. 
1b). Thus, the failure of intranasal 5-OP-RU alone to drive MAIT cell enrichment was not 
necessarily the result of the lability of the antigen, suggesting that MAIT cell accumulation and 
enrichment requires stronger signals than those needed for activation. Indeed, repeated (x6) intranasal 
administration of 5-OP-RU alone over a seven-day period was still an insufficient stimulus to induce 
MAIT cell accumulation, despite sustained Ag exposure (Fig. 2f). Taken together, these findings 
demonstrate that Rib-defective (and thus MAIT cell antigen deficient) bacteria and TLR agonists are 
independently capable of providing a co-stimulus that helps drive MAIT cell accumulation and 
enrichment in response to 5-OP-RU antigen in vivo (Fig. 2c,d). 
 
Infection induces IL-17 production, an increase in T-bet expression and the long-lived retention 
of phenotypically effector/memory MAIT cells in situ 
Upon activation in vitro, MAIT cells produce IFN, TNF and IL-174,8,13,34. This pattern of cytokine 
expression was mirrored following intranasal inoculation with S. Typhimurium (Fig. 3, 
Supplementary Fig. 5, 6). Most striking was the production of IL-17, which was detected in 
approximately 50% of lung MAIT cells directly ex vivo at d7 without further stimulation (Fig. 3). 
Interestingly, MAIT cells still appeared ‘primed’ to rapidly secrete IL-17 long-term p.i. (Fig. 3), 
 8 
suggesting that MAIT cells acquire rapid responsiveness as they differentiate into their memory 
phase. In contrast, a higher proportion of non-MAIT -T cells than MAIT cells produced IFN and 
TNF 7 days p.i. (Fig. 3, Supplementary Fig.  4).  
 
The transcriptional factor promyelocytic leukemia zinc finger (PLZF) is a master regulator of innate-
like T cell development, including Natural Killer T cells and some T cells35. Both human and 
mouse MAIT cells express PLZF19,24. Notably, we found that PLZF was expressed by nearly all lung 
MAIT cells both before and after infection, along with the orphan nuclear receptor, RORt, which 
plays a key role in differentiation of Th17 cells36 and is expressed by human and mouse MAIT 
cells24,34 (Fig. 4a, Supplementary Fig. 5). In addition, we examined the expression of the 
transcription factor T-bet, a key regulator of Th1 type immunity37. T-bet is reported to suppress IL-17 
expression and promote Th1 development, whereas loss of T-bet expression can induce commitment 
to Th2 and loss of IFN expression38-40. The expression of RORt declined slightly in MAIT cells as 
T-bet expression levels increased from d7-d142 p.i. Interestingly, the majority of cells at d142 co-
expressed the two transcription factors (Fig. 4b, Supplementary Fig. 5). The production of IL-17 by 
MAIT cells d7 p.i. ex vivo or following PMA stimulation, was observed in the presence of either T-
bet or RORt (or both) (Fig. 4c, Supplementary Fig. 6). In contrast, at the same time point, a much 
smaller proportion of MAIT cells produced IFN after PMA stimulation and most of these expressed 
T-bet. This pattern was also true for IFN production by non-MAIT cells (Fig. 4c). IL-17 and IFN 
appeared to be independently expressed by MAIT cells, as shown by co-staining (Supplementary 
Fig. 7). 
 
Even before infection, CD44, a cell adhesion molecule highly expressed on memory T cells, was 
expressed by most MAIT cells. In contrast, a smaller proportion of non-MAIT -T cells expressed 
CD44 pre- and post infection (Fig. 5). CD62L (L-selectin) is highly expressed on naïve T cells, and 
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is used to further distinguish central memory (CD62L+) from effector memory (CD62L−). The 
regulation of CD62L plays a pivotal role in controlling the traffic of conventional T lymphocytes 
through peripheral lymph nodes, with CD62L shed from the cell membrane following activation41. 
Not surprisingly CD62L remained low on lung MAIT cells at all three phases: homeostatic MAIT 
cells in the absence of infection, activated MAIT cells (during infection) and antigen experienced 
MAIT cells (>d30 p.i.) (Fig. 5). These observations are consistent with the effector/memory 
phenotype previously described for human MAIT cells34.  However, the proportion of MAIT cells 
expressing the activation marker CD69 increased from ~20% pre-infection to 90% post-infection 
(Fig. 5b) consistent with our other results showing that further activation of MAIT cells occurred 
following infection. MAIT cells from the lungs of uninfected mice also showed CD25 expression 
(not shown). 
 
To measure the contribution of recruitment from blood or other sites, we examined MAIT cell 
enrichment in lung and draining LN versus possible loss in other organs for 7 weeks p.i. with 
BRD509 (Fig. 6a,b). The enrichment of MAIT cells as a proportion of all -T cells was most 
evident in the lungs of infected mice (d7, 35-50% of -T cells), but was only evident in the draining 
LN and spleen at wk7 (Fig. 6a,b), suggesting redistribution to these sites during the resolution phase 
of the infection (Fig. 6c). No MAIT cell loss was observed in the spleen or draining LN, where the 
percentage of MAIT cells remained stable throughout the infection course and increased slightly 
during the late course (Fig. 6a,b). 
 
Together, our data show a rapid MAIT cell response to bacterial lung infection, which was dependent 
on MR1 presentation of riboflavin biosynthesis-derived ligands. MAIT cell accumulation and 
proliferation, but not CD69 up-regulation, was dependent on second signals, which could be 
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furnished through TLR ligation or by bacteria. Cell surface markers and cytokine production were 
consistent with an effector/memory phenotype. 
 
DISCUSSION 
We have developed a model bacterial infection in mice to evaluate the importance of the riboflavin 
synthesis pathway in driving MAIT cell responses in vivo, and to define the phenotypic and 
functional characteristics of the responding MAIT cells. The generation of highly specific MR1-
antigen tetramers2,8 has allowed the precise Ag-dependent definition of MAIT cells, which are much 
less abundant in wild-type mice than humans9, overcoming potential confusion engendered by using 
surrogate markers of MAIT cells or transgenic mice. Using MR1-Ag-tetramers, we show that MAIT 
cells are readily detectable, albeit in low numbers, in wild-type C57BL/6 mice, being most abundant 
in the reproductive tract, lung and liver. We exploited the capacity of S. Typhimurium, which we 
previously showed to potently activate MAIT cells in vitro2,4 as a model to analyse MAIT cell 
responses and activation requirements in vivo, with the respiratory tract providing an accessible organ 
to assess MAIT activation. S. Typhimurium is a gastrointestinal pathogen of humans and a systemic 
pathogen of mice. Clearance of S. Typhimurium in mice is achieved through a number of redundant 
cellular mechanisms, including CD4+, and to a lesser extent CD8+, T cells26. In our respiratory model, 
lung clearance was independent of the presence of MAIT cells, suggesting their redundancy as 
protective T cells in this model too. It would be interesting to establish whether the type or kinetics of 
the non-MAIT immune response differed in the absence of MAIT cells. Nevertheless, intranasal 
infection of mice led to a substantial increase in MAIT cells in the lung to up to 50% of all 
pulmonary -T cells (a ~200-fold increase in absolute numbers versus ~5 fold for non-MAIT T 
cells). This enrichment peaked at d7 and was MR1-dependent, as shown genetically (in MR1-/- mice) 
and by anti-MR1 mAb blocking, consistent with previous in vitro data1-6. The accumulation of MAIT 
cells was directly related to the size of the bacterial inoculum. Interestingly, expanded MAIT cells 
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were long-lived in the lung and other tissues, persisting in higher numbers than found in uninfected 
mice long after S. Typhimurium was cleared to undetectable levels (~10 weeks). It is interesting to 
speculate that a history of infection in humans could explain the higher proportion of MAIT cells 
compared to SPF-housed mice, and it will be exciting to discover the role of MAIT cells in immune 
protection against a range of microbial respiratory pathogens. 
 
Genetic manipulation of S. Typhimurium allowed us to demonstrate that responsiveness of MAIT 
cells in vivo required an intact riboflavin pathway, and hence was abolished upon disruption of the 
key RibD gene responsible for generating the precursor 5-A-RU, which generates the dominant 
MAIT cell ligand, 5-OP-RU. Notably, the BRD509ribDH mutant could still induce weak, transient 
up-regulation of MAIT cell CD69 in vitro, but did not induce accumulation or enrichment of MAIT 
cells in vivo. It remains unclear whether there are natural MAIT cell antigens derived from pathways 
other than riboflavin synthesis. The variability of MAIT TCRs from the semi-invariant MAIT TCR 
combinations7,8,22 suggests that these receptors may be selected by alternate ligands and MAIT cells 
have an apparent capacity o discriminate between pathogen-derived ligands in a clonotype-dependent 
manner21. On the other hand, the semi-invariant V and restricted V chain usage, the importance of 
the conserved Tyr 95 residue across the TRAJ33, TRAJ20 and TRAJ12 gene segments tested to 
date and the stereotypic mode of binding of the MAIT TCR to all known ligands and analogues 
studied1,2,4,20,22, suggest a limited ligand family is recognized by MAIT cells. Accordingly, the 
abrogation of MAIT cell accumulation and activation following mutagenesis of the riboflavin 
synthesis pathway implies that this pathway furnishes the dominant, and likely exclusive, family of 
natural antigens recognized by MAIT cells at least for S. Typhimurium. 
 
Previous studies have shown that MAIT cells can be directly activated via non-TCR signals including 
IL-12 and IL-1844,45, and control of F. tularensis intracellular growth required the IL-12 40 kDa 
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subunit, implying a need for additional signals from infected APCs13. These observations are 
consistent with our finding that a co-stimulus was required to induce MAIT cell accumulation in the 
lungs following intranasal administration of synthetic MAIT cell antigen, 5-OP-RU, even when 
delivered repeatedly over 7 days, and despite inducing MAIT cell up-regulation of CD69. In contrast, 
intranasal administration of 5-OP-RU plus the TLR agonists Pam2Cys (TLR2/6), poly I:C (TLR3) or 
CpG (TR9) induced enrichment of lung MAIT cells to the approximate level achieved by S. 
Typhimurium infection. Importantly, addition of 5-OP-RU during intranasal challenge with bacteria 
lacking the riboflavin synthesis pathway (BRD509ribDH mutant) restored their capacity to induce 
MAIT cell accumulation in the lungs, indicating that co-stimulatory capacity is inherent in bacterial 
infection and plays a role in the expansion and responsiveness of MAIT cells. 
 
The phenotype of MAIT cells that expand in response to infection with S. Typhimurium is consistent 
with previous studies of in vitro stimulated MAIT cells, in that they express activation markers even 
before infection and produce pro-inflammatory cytokines IL-17, IFN and TNF upon activation by 
microbes. This is also consistent with a study of pulmonary infection of mice with Francisella 
tularensis13, although of note, this study defined MAIT cells as DN thus not addressing a potential 
role for CD8+ or CD4+ MAIT cells in response to infection. The expression of CD69 on 20% of 
MAIT cells, compared to ~4% of non-MAIT T cells in the steady state is intriguing, and could 
suggest that there may be stimulation of MAIT cells through the presence of commensal microbes 
providing antigen at mucosal sites. As well as being described as an early-activation marker, CD69 
expression has been previously shown on human tissue resident memory T cells46 and to play a role 
in tissue retention of T cells47. However, further stimulation of MAIT cells, and CD69 up-regulation,  
could be induced by infection or provision of antigen plus co-stimulatory signals. The expansion of 
MAIT cells following infection may be a consequence of the lower number of MAIT cells in mice 
versus humans. Interestingly, once expanded, the MAIT cells are long lived in primary tissues, 
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preserving their activation and homing phenotype, maintaining expression of their transcriptional 
signature PLZF and RORt but with gradual increase in the level of T-bet, known to coordinate 
developmental and effector programs some of which are conserved across adaptive and innate T cells.  
 
Our study presents a picture of MAIT cell responsiveness to pathogens that bridges attributes of 
innate and adaptive immunity, but that is dependent on specific antigen expressed by the infecting 
pathogen. It will be fascinating to unravel whether these cells have evolved in response to a range of 
pathogens with shared antigen(s), or whether they have a more focused role, perhaps involving a 
single pathogen family possibly at a key site. 
 
METHODS 
In vitro activation assay. Jurkat cells expressing a MAIT TCR comprising the TRAV1-2-TRAJ33 
-chain, and TRBV6-1 -chain (Jurkat.MAIT), were co-incubated with filtered bacterial culture 
supernatant and C1R APCs expressing MR1 (CIR.MR1) for 16 h, and stained with anti-CD3-PE and 
anti-CD69-APC antibodies before flow cytometric analysis. Activation of Jurkat.MAIT cells was 
measured by an increase in surface CD69 expression. 
 
Compounds and immunogens. 5-OP-RU was prepared as described previously2. 6-FP was 
purchased from Schircks Laboratories. TLR2/6 agonist Pam2Cys48 were chemically synthesized and 
functionally verified. CpG1688 (Sequence: T*C*C*A*T*G*A*C*G*T*T*C*C*T*G*A*T*G*C*T 
(* phosphorothioate linkage) nonmethylated cytosine-guanosine oligonucleotides was purchased 
from Geneworks (Australia). Poly (I:C) (HMW VacciGrade) was purchased from InvivoGen (USA). 
 
Bacterial strains and mutants. S. Typhimurium BRD509, (previously described49,50) harbours 
deletions in aroA and aroD, resulting in limitation of replication of bacteria27,49 and has an intact 
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riboflavin synthesis pathway. The BRD509ΔribDH mutant, lacking a gene segment containing ribD 
and ribH, which encode key enzymes in the riboflavin synthesis pathway, was constructed by lamda 
red-recombinase mediated allelic replacement followed by transduction using phage P22 as 
previously described27. BRD509ΔribDH cultures were supplemented with 20 µg/ml riboflavin. 
 
BRD509ΔribDH complemented by transformation of ribDH genes resulted in strain 
BRD509ΔribDH+ribDH. Mutation and reconstitution were verified by lack of growth or growth on 
Luria Agar, and by PCR. Bacteria were cultured at 37 °C statically, in Luria Bertani broth (LB) with 
appropriate antibiotics for 16-18 h to log-phase (OD600 0.6-0.9). Supernatant was collected by 
centrifugation, filtered (0.22 µM) and stored at -80oC until use. For the infecting inoculum, bacteria 
were re-inoculated in pre-warmed medium for a further 2-4 h static culture (OD600 0.4-0.6). With the 
estimation that 1 OD600=5x108/ml, sufficient bacteria were washed and diluted in PBS for intranasal 
delivery to mice. A sample of inoculum was plated onto Luria Agar with appropriate antibiotics for 
verification of bacterial concentration by counting CFU. 
 
Mice and inoculations. Mice were bred and housed in the Biological Research Facility of the Peter 
Doherty Institute. MR1-/- mice were generated by breeding Vα19i.Cα-/-.MR1-/- mice18 (from 
Susan Gilfillan, Washington University, St. Louis School of Medicine, St. Louis, MO) with C57BL/6 
mice, and inter-crossing of F1 mice. The genotype was determined by tail DNA PCR at the MR1 
locus and by the presence of intact -T cells in blood using Ab against TCR. The absence of 
MAIT cells was verified by flow cytometry in the retired founder breeder mice. Male mice aged 6-12 
weeks were used in experiments, after approval by the University of Melbourne Animal Ethics 
Committee. 
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Intranasal inoculation with S. Typhimurium (BRD509: 106 or BRD509ribDH: 107 unless otherwise 
stated) or antigens (76 pmol 5-OP-RU or 6-FP alone, or plus 20 nmol Pam2Cys, 20 g CpG or 50 g 
poly I:C) in 50 µl per nares was performed on anesthetized mice. For blocking experiments, mice 
were given 250 µg anti-MR1 (26.5 or 8F2.F9)28,29 or isotype control mAbs in 200 µl PBS, once (i.v 
or i.p) 1 day prior to inoculation and twice (d1, d4) post inoculation. Mice were killed by 
administration of CO2 and organs: lung (following heart perfusion with 10 ml cold RPMI), liver 
(following portal vein perfusion with 10 ml PBS), mediastinal lymph nodes, blood, spleen, thymus, 
vagina and uterus were taken. 
 
Preparation of organs and isolation of cells. To prepare single cell suspensions, lungs, uterus and 
vagina (pooled from 3 mice) were finely chopped with a scalpel blade and treated with 3 mg/ml 
collagenase III (Worthington), 5 g/ml DNAse and 2% FCS in RPMI for 90 min at 37 °C with gentle 
shaking. Cells were then filtered (70 µM) and washed with PBS/2% FCS. Liver lymphocytes were 
prepared by pushing through metal mesh, followed by Percoll (33.75%) density gradient 
centrifugation (693 g, 12 mins, RT). LNs, spleen and thymus were prepared by pushing the tissues 
through 70 µM cell strainers. RBCs were lysed from lung, liver and spleen preparations with 
hypotonic buffer TAC (Tris-based Amino Chloride) for 5 min at 37 °C. Approximately 1.5×106 cells 
were filtered (40 µm) and used for flow cytometric analysis. Blood cells were prepared by 
centrifugation and serum removal. RBC lysis was by Lysing buffer (BD Biosciences) after flow 
cytometric staining. 
 
Determination of bacterial counts in infected lungs. Bacterial colonisation was determined by 
counting CFU obtained from plating homogenized organs from infected mice (5 or more per group) 
on Luria agar containing appropriate antibiotics and supplements. 
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Generation of soluble MR1 tetramers. Murine MR1 and β2-Microglobulin genes were expressed in 
E. coli inclusion bodies, refolded and purified as described previously20. MR1-5-OP-RU and MR1-6-
FP tetramers were generated as described previously2.  
 
Antibodies and flow cytometry. Ab against CD19 (1D3, PerCP-Cy 5.5), CD3 (UCHT1, PE or 145-
2C11, PE-Cy7), CD4 (GK1.5, APC-Cy7), CD45.2 (104, FITC), CD69 (FN50, APC), CD8α (53-6.7, 
PE), IFN (XMG1.2, PE-Cy7), TCRβ (H57-597, APC or FITC), CD44 (IM7, PE), TNF (MP6-XT22, 
PE) and IL-17A (TC11-18H10, AlexaFluor700) were purchased from BD. Ab against MHC II (M5, 
AlexaFluor700), CD69 (H1.2F3, PE), CD25 (PC61.5, APC), PLZF (Mags.21F7, PE), RORt (B2D, 
APC) and T-bet (4B10, PE-Cy7) were purchased from eBioscience. Ab against CD62L (Mel-14, 
FITC) was purchased from Biolegend. Blocking Ab (26.5, 8F2.F9) and isotype controls (3E12, 8A5) 
were prepared in house. To block non-specific staining, cells were incubated with MR1-6FP tetramer 
and anti-Fc receptor (2.4G2) for 15 min at RT, then incubated at RT with antibody/tetramer cocktails 
in PBS/2% FCS. 7-AAD (5 µL/sample) was added for the last 10 min. Cells were fixed with 1% PFA 
prior to analysis on LSRII or LSR Fortessa (BD Bioscience) flow cytometers. Data analysis was 
performed with FlowJo software. For intracellular cytokine staining (ICS), Golgi plug (BD 
Biosciences) was used during all processing steps. Cells stimulated with PMA/Ionomycin (20 ng/ml, 
1 μg/ml respectively) for 3 h at 37 were included as positive controls. Surface staining was 
performed at 37oC and cells stained for intracellular cytokines using the BD 
Fixation/Permeabilisation kit or transcription factors using the transcription buffer staining set 
(eBioscience) according to the manufacturers’ instructions. 
 
Statistical analysis. Statistical tests were performed using Prism GraphPad software (version 6). 
Comparisons between groups were performed using Student’s t test, unless otherwise stated. 
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FIGURE LEGENDS 
Figure 1. MAIT cells respond to Salmonella Typhimurium in vivo. A) Representative plots and 
scatter plots showing MAIT cell percentage among TCRβ+ lymphocytes in a range of organs from 5 
uninfected C57BL/6 mice. MAIT cells are defined by positive MR1-tetramer and TCRβ staining. 
Numbers represent MAIT cells as a percentage of TCRβ+ lymphocytes. B) Representative plots 
showing TCR+ lymphocytes (with percentage of MAIT cells) harvested from lungs of uninfected 
C57BL/6, or infected (d7 p.i. with 106 S. Typhimurium BRD509) C57BL/6 or C57BL/6 MR1-/- mice. 
C) Treatment of mice with anti-MR1 mAb 26.5, but not an isotype control, blocked the accumulation 
of MAIT cells upon S. Typhimurium infection. Three mice per group were injected with 0.25 mg 
indicated antibodies or no Ab i.p. 1 day prior to infection and three times p.i. (d1, d3 and d5). 106 
BRD509 were inoculated i.n. at d0. At d7 p.i. mice were killed and lung cells were examined for 
MAIT cell accumulation. Statistics were performed using Student’s t test (**: p<0.01, error bars: 
SEM). Uninfected MR1-/- mice were used as the negative control. The experiment was performed 
twice with similar results. D) Dose (of S. Typhimurium BRD509) response of MAIT cells as a 
percentage of TCR+ cells at d7 p.i. Five mice per group were examined (Mean +/- SEM). The 
experiment was performed three times with similar results. E) Absolute numbers of MAIT cells 
(circle), conventional non-MAIT cells (triangle) and total TCR+ cells (square) recovered from lungs 
were expressed over a time course following intranasal infection with 106 S. Typhimurium BRD509. 
Five mice per group were examined (Mean +/- SEM). The experiment was performed twice with 
similar results. 
 
Figure 2. MAIT cells response depends on both specific riboflavin synthesis-derived antigen and co-
stimulation. A) In vitro activation. Jurkat.MAIT cells were incubated for 6 h with filtered culture 
supernatant from BRD509 or BRD509ribDH mutant (ribDH) or reconstituted mutant 
BRD509ribDH+RibDH S. Typhimurium in the presence of C1R.MR1 cells. Activation was 
 21 
detected by staining with anti-CD69. Data shows mean MFI of gated Jurkat.MAIT cells with SEM as 
error bars. The experiment was performed more than three times with similar results. B) and C) In 
vivo accumulation of MAIT cells by BRD509 and BRD509ribDH S. Typhimurium. B) 
Representative plots, and C) MAIT cells as a percentage of -T cells, from the lungs of mice 
immunised with BRD509 (106) or BRD509ribDH (107) Salmonella (i.n. once), in combination with 
5-OP-RU or 6-FP (50 l of 1.52 M i.n.) three times at d1, d3 and d5 p.i. Day 7 p.i. data are shown. 
Three mice per group were examined (Mean +/- SEM, Student’s t test**; p < 0.05). The experiment 
was performed twice with similar results. D) MAIT cells as a percentage of -T cells in the lungs of 
mice immunised i.n. with S. Typhimurium BRD509 (106), or combinations of Pam2Cys (20 nmol, 
i.n), CpG (20 g/mouse, i.n.), or poly I:C (50 g/mouse, i.n.) and/or 5-OP-RU or 6-FP (50 l 
containing 76 pmol M i.n.). 5-OP-RU or 6-FP was administered twice i.n. 1 and 3 days after 
Pam2Cys, CpG or poly I:C administration. Day 7 post inoculation data shown for 6 individual mice 
with mean +/- SEM. The experiment was performed twice with similar results. E) Mice were 
administered i.n with combinations of Pam2Cys (20 nmol/5 l per mouse) and/or MAIT cell ligands 
(5-OP-RU, 6-FP, 45 l of 1.52  l of PBS, per mouse). Data represents MFI of CD69 
expression on MAIT and non-MAIT T cells for individual mice and mean +/- SEM, 2 h post 
inoculation. F) Mice were inoculated i.n. with indicated MR1 ligands and/or co-stimulator as shown 
in schematic. Percentages of MAIT cells of T cells are shown, from 2 mice (control groups): 
uninfected, Pam2cys (day 0) plus 5-OP-RU/6FP (day 0, 1, 2 and 4); or 3 mice each: 6 times of 5-OP-
RU/6FP alone (day 0, 1, 2, 3, 4 and 5). 
 
Figure 3. Cytokine profiling and phenotyping of MAIT cells upon infection with S. Typhimurium 
BRD509. Intracellular cytokine staining of MAIT and non-MAIT -T cells at d7 p.i. detected 
directly ex vivo, or following stimulation with PMA and ionomycin. A) representative plots and B) 
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scatter plots showing individual mice and mean +/- SEM from 3 mice (pooled for uninfected). The 
experiment was performed twice with similar results. MAIT and non-MAIT T cells are defined as 
live, CD19-, TCR+, Tet+ and live, CD19-, TCR+, Tet- cells respectively. 
 
Figure 4. MAIT cell expression of transcription factors PLZF, RORt and T-bet. A) Expression of 
transcription factors on MAIT cells in uninfected or infected mice at indicated time points. B) Co-
staining of cells with RORt and T-bet shown as representative plots and individual mice from one 
experiment. C) Cytokine profile as in Fig. 3, but showing RORt and T-bet expression. The 
experiment was performed three times with similar results. 
 
Figure 5. MAIT cells maintain an effector memory phenotype following infection. Analysis of 
phenotypic and activation marker expression on MAIT cells isolated from the lungs of mice infected 
i.n. with 106 S. Typhimurium BRD509 at indicated time points. A). Representative plots. B). 
Percentages among MAIT and non-MAIT cells expressing markers for individual mice. The 
experiment was performed twice with similar results. 
 
Figure 6. MAIT cells proliferate in the lungs and draining LN in response to intranasal infection. A) 
Kinetics of MAIT cell accumulation in lungs, mediastinal draining LN and spleen at indicated times 
p.i. from C57BL/6 inoculated with BRD509 i.n. The experiment was performed three times with 
similar results. Data represent mean ± SEM from five mice per group. Data from C57BL/6.MR1-/- 
mice are not shown. B) MAIT cell percentage in various organs 7 weeks after i.n. S. Typhimurium 
BRD509 inoculation. Same data as in A, shown in bar graphs for ease of comparison. C) Bacterial 
load (CFU) recovered from lungs of C57BL/6 or C57BL/6.MR1-/- mice  inoculated i.n. with 106 S. 
Typhimurium BRD509. Individual mice (5 per group) and mean are shown. The experiment was 
performed 3 times with similar results. 
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Supplementary Material 
Supplementary Figure 1. Anti-MR1 blocking of MAIT cell accumulation and CD69 upregulation. 
A. Treatment of mice with anti-MR1 mAb 8F2.F9, but not an isotype control, blocked the 
accumulation of MAIT cells upon S. Typhimurium infection. Mice were injected with 0.25 mg 
indicated antibodies or no Ab i.p. 1 day prior to infection and at d1, d3 and d5 p.i. 106 BRD509 were 
inoculated i.n. at d0. At d7 p.i. mice were killed and lung cells were examined for MAIT cell 
accumulation. Student’s t test (**: p<0.01, error bars: SD). The experiment was performed twice with 
similar results. B. Mice were inoculated i.n with combinations of Pam2Cys (Pam) (20 nmol/5 l per 
mouse) and/or MAIT cell ligands (5-OP-RU, 6-FP, 45 l of 1.52  l of PBS, per mouse). 
Data represents Mean +/- SEM MFI of CD69 expression on MAIT and non-MAIT T cells 2 h post 
inoculation. For blocking 0.25 mg anti-MR1 mAb 8F5 was given 1 day prior. 
 
Supplementary Figure 2. Bacterial counts recovered from the lungs following infection. CFU of S. 
Typhimurium recovered from the lungs at indicated time points after infection in C57BL/6 (B6) and 
MR1-/- mice after infection with rib sufficient (BRD509) and deficient (BRD509ribDH) strains. 
Mean +/- SEM of 5 mice per group. The experiment was performed twice with similar results. For 
clarity lines are shown for C57BL/6 groups only with markers for both C57BL/6  (open symbols) and 
MR1-/- mice (closed symbols). 
 
Supplementary Figure 3. In vivo accumulation of MAIT cells with ligands delivered i.v. MAIT 
cells as a percentage of -T cells, from the lungs of mice immunised with BRD509 (106) or 
BRD509ribDH (107) Salmonella (i.n. once), in combination and followed with 5-OP-RU or 6-FP 
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(76 pmol in 100 l i.v.) three times at d1, d3 and d5 p.i. Day 7 p.i. data are shown. Two or three mice 
per group were examined (error bar=SD). The experiment was performed twice with similar results. 
 
Supplementary Figure 4. Cytokine production by non-MAIT T cells upon infection with S. 
Typhimurium BRD509. Percentage of non-MAIT -T cells producing indicated cytokines at d7 p.i. 
detected by intracellular cytokine staining directly ex vivo, or following stimulation with PMA and 
ionomycin, as in Figure 3. Individual mice with mean +/- SEM are shown. 
 
Supplementary Figure 5. PLZF, RORt and T-bet expression by MAIT and non-MAIT T cells. 
Shown is mean fluorescence intensity (MFI) from gated cells from individual mice from the same 
experiment in Figure 4, direct ex vivo samples. Bars = mean +/- SEM. 
 
Supplementary Figure 6. Cytokine production and transcription factor expression by MAIT cells. 
Shown is percentage of transcription factor positive and negative MAIT cells which produce each 
cytokine. Individual mice from the same experiment in Figure 4c, direct ex vivo samples are shown. 
Bars = mean +/- SEM. 
 
Supplementary Figure 7. Co-staining of IFN and IL-17 from lung MAIT cells following infection. 
Shown are MAIT cells from one representative mouse per group from the same experiment shown in 
Figure 4b, direct ex vivo and PMA-stimulated samples. 
